Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Université de Montréal

$120,000.00

Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial

EF 2025-26

Résumé
Prostate cancer is the most common cancer among men. For patients with more advanced forms that remain confined to the prostate, treatment usually involves external radiation to the whole prostate, combined with an additional "boost" of internal radiation (brachytherapy). This boost improves cancer control but often increases urinary side effects. When prostate cancer recurs, it almost always returns in the same area where the tumor first developed. With modern imaging technologies, such as magnetic resonance imaging (MRI), doctors can now pinpoint the tumor's exact location within the prostate during treatment. This makes it possible to explore a more targeted approach, delivering internal radiation only to the tumor itself, rather than to the entire prostate. This clinical trial is evaluating whether this focused method of internal radiotherapy can reduce urinary side effects without compromising treatment effectiveness. In the study, 150 patients with advanced localized prostate cancer will be randomly assigned to receive either the standard treatment (whole-prostate internal radiation plus external radiation) or the experimental treatment (focal internal radiation targeting only the tumor, plus external radiation). The primary goal is to determine whether fewer patients in the experimental group experience significant declines in urinary function, measured through patient-reported questionnaires. Researchers will also monitor other side effects and cancer control outcomes over time.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559369
Name
Belliveau Colin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Brackytherapy; Cancer; Clinical Trial; Imaging; Mri; Prostate; Quality Of Life; Radiotherapy
Abstract
Prostate cancer is the most common cancer among men. For patients with more advanced forms that remain confined to the prostate, treatment usually involves external radiation to the whole prostate, combined with an additional "boost" of internal radiation (brachytherapy). This boost improves cancer control but often increases urinary side effects. When prostate cancer recurs, it almost always returns in the same area where the tumor first developed. With modern imaging technologies, such as magnetic resonance imaging (MRI), doctors can now pinpoint the tumor's exact location within the prostate during treatment. This makes it possible to explore a more targeted approach, delivering internal radiation only to the tumor itself, rather than to the entire prostate. This clinical trial is evaluating whether this focused method of internal radiotherapy can reduce urinary side effects without compromising treatment effectiveness. In the study, 150 patients with advanced localized prostate cancer will be randomly assigned to receive either the standard treatment (whole-prostate internal radiation plus external radiation) or the experimental treatment (focal internal radiation targeting only the tumor, plus external radiation). The primary goal is to determine whether fewer patients in the experimental group experience significant declines in urinary function, measured through patient-reported questionnaires. Researchers will also monitor other side effects and cancer control outcomes over time.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Belliveau, Colin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~